Knight Therapeutics (TSX:GUD) - Share price, News & Analysis

GUD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

GUD Stock Overview

Risk Analysis

No risks detected for GUD from our risk checks.

Knight Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Knight Therapeutics
Historical stock prices
Current Share Price	CA$5.22
52 Week High	CA$5.74
52 Week Low	CA$5.01
Beta	0.53
1 Month Change	-2.43%
3 Month Change	0.19%
1 Year Change	-4.22%
3 Year Change	-32.38%
5 Year Change	-49.27%
Change since IPO	36.29%

Shareholder Returns

	GUD	CA Pharmaceuticals	CA Market
7D	1.4%	-0.3%	0.3%
1Y	-4.2%	-70.9%	-4.0%

Return vs Industry: GUD exceeded the Canadian Pharmaceuticals industry which returned -70.9% over the past year.

Return vs Market: GUD matched the Canadian Market which returned -4.1% over the past year.

Price Volatility

Is GUD's price volatile compared to industry and market?
GUD volatility
GUD Average Weekly Movement	2.5%
Pharmaceuticals Industry Average Movement	11.7%
Market Average Movement	10.0%
10% most volatile stocks in CA Market	17.3%
10% least volatile stocks in CA Market	4.4%

Stable Share Price: GUD is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GUD's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	660	Samira Sakhia	https://www.gud-knight.com

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation.

Knight Therapeutics Fundamentals Summary

How do Knight Therapeutics's earnings and revenue compare to its market cap?
GUD fundamental statistics
Market Cap	CA$601.81m
Earnings (TTM)	-CA$6.69m
Revenue (TTM)	CA$261.22m

2.3x

P/S Ratio

-89.9x

P/E Ratio

Is GUD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GUD income statement (TTM)
Revenue	CA$261.22m
Cost of Revenue	CA$133.91m
Gross Profit	CA$127.31m
Other Expenses	CA$134.00m
Earnings	-CA$6.69m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.058
Gross Margin	48.74%
Net Profit Margin	-2.56%
Debt/Equity Ratio	4.9%

How did GUD perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is GUD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GUD?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for GUD. This is calculated by dividing GUD's market cap by their current preferred multiple.
What is GUD's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CA$601.81m

GUD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	11.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GUD's PS Ratio compare to its peers?

GUD PS Ratio vs Peers

The above table shows the PS ratio for GUD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	1.9x

Forward PS

Price-To-Sales vs Peers: GUD is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.9x).

Price to Earnings Ratio vs Industry

How does GUD's PE Ratio compare vs other companies in the Canadian Pharmaceuticals Industry?

Price-To-Sales vs Industry: GUD is expensive based on its Price-To-Sales Ratio (2.3x) compared to the Canadian Pharmaceuticals industry average (2x)

Price to Sales Ratio vs Fair Ratio

What is GUD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GUD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.3x
Fair PS Ratio	0.8x

Price-To-Sales vs Fair Ratio: GUD is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Share Price vs Fair Value

What is the Fair Price of GUD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GUD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GUD's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GUD's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Knight Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

117.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GUD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GUD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GUD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GUD's revenue (6.3% per year) is forecast to grow slower than the Canadian market (7.3% per year).

High Growth Revenue: GUD's revenue (6.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GUD is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Knight Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

4.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GUD is currently unprofitable.

Growing Profit Margin: GUD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: GUD is unprofitable, but has reduced losses over the past 5 years at a rate of 4.5% per year.

Accelerating Growth: Unable to compare GUD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GUD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).

Return on Equity

High ROE: GUD has a negative Return on Equity (-0.81%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Knight Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: GUD's short term assets (CA$331.0M) exceed its short term liabilities (CA$121.3M).

Long Term Liabilities: GUD's short term assets (CA$331.0M) exceed its long term liabilities (CA$44.5M).

Debt to Equity History and Analysis

Debt Level: GUD has more cash than its total debt.

Reducing Debt: Insufficient data to determine if GUD's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: GUD's debt is well covered by operating cash flow (98.2%).

Interest Coverage: Insufficient data to determine if GUD's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

Dividend

What is Knight Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GUD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GUD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GUD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GUD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GUD has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure

CEO

Samira Sakhia (53 yo)

5.83yrs

Tenure

CA$1,098,852

Compensation

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...

CEO Compensation Analysis

Compensation vs Market: Samira's total compensation ($USD850.70K) is below average for companies of similar size in the Canadian market ($USD1.24M).

Compensation vs Earnings: Samira's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: GUD's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

Experienced Board: GUD's board of directors are considered experienced (5.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: GUD insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/26 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31